Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD OTCMKTS:CRLBF NASDAQ:CURR NASDAQ:DBVT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$12.13+1.0%$12.37$4.88▼$19.58$260.57MN/A39,139 shs36,180 shsCRLBFCresco Labs$0.62+4.5%$0.56$0.43▼$2.05$291.37M1.42798,477 shs1.30 million shsCURRCurrenc Group$1.99+10.6%$1.09$0.33▼$13.59$83.75M-0.142.71 million shs695,290 shsDBVTDBV Technologies$9.00+5.8%$9.50$2.20▼$12.78$233.09M-0.5826,058 shs24,525 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+1.00%-17.48%-10.28%-5.68%+1,212,999,900.00%CRLBFCresco Labs+3.33%-9.30%+21.35%-31.11%-61.25%CURRCurrenc Group+10.56%-13.10%+120.77%+41.13%+198,999,900.00%DBVTDBV Technologies+5.76%-5.95%-12.62%+0.56%+85.57%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACRLBFCresco Labs1.125 of 5 stars0.05.00.00.01.40.01.3CURRCurrenc GroupN/AN/AN/AN/AN/AN/AN/AN/ADBVTDBV Technologies3.6428 of 5 stars4.45.00.00.00.92.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$33.00172.05% UpsideCRLBFCresco Labs 3.00BuyN/AN/ACURRCurrenc Group 3.50Strong Buy$3.5075.88% UpsideDBVTDBV Technologies 2.80Moderate Buy$14.7563.89% UpsideCurrent Analyst Ratings BreakdownLatest CURR, CRLBF, DBVT, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2025AARDAardvark TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$40.006/26/2025DBVTDBV TechnologiesLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/26/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$21.006/3/2025CRLBFCresco LabsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Moderate Buy5/29/2025DBVTDBV TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeSell$7.255/27/2025DBVTDBV TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform5/27/2025DBVTDBV TechnologiesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.005/15/2025AARDAardvark TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/5/2025DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $16.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/ACRLBFCresco Labs$724.34M0.42N/AN/A$0.79 per share0.78CURRCurrenc Group$46.44M1.99N/AN/A($0.90) per share-2.21DBVTDBV Technologies$4.15M59.40N/AN/A$3.15 per share2.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$20.59MN/A0.00∞N/AN/AN/AN/AN/ACRLBFCresco Labs-$74.44M-$0.24N/AN/AN/A-11.86%-21.77%-6.00%8/7/2025 (Estimated)CURRCurrenc Group-$39.47MN/A0.00∞N/AN/AN/A-38.11%8/19/2025 (Estimated)DBVTDBV Technologies-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%N/ALatest CURR, CRLBF, DBVT, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/19/2025Q2 2025CURRCurrenc Group-$0.04N/AN/AN/AN/AN/A8/7/2025N/ACRLBFCresco Labs-$0.03N/AN/AN/A$162.00 millionN/A7/29/2025Q2 2025DBVTDBV Technologies-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 million5/30/2025Q1 2025CRLBFCresco Labs-$0.03-$0.04-$0.01-$0.04$164.37 million$165.76 million5/20/2025Q1 2025CURRCurrenc Group-$0.04-$0.13-$0.09-$0.13$10.50 million$10.06 million5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/ACRLBFCresco LabsN/AN/AN/AN/AN/ACURRCurrenc GroupN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A25.8625.86CRLBFCresco Labs1.632.751.98CURRCurrenc GroupN/A0.610.61DBVTDBV TechnologiesN/A2.450.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/ACRLBFCresco Labs0.05%CURRCurrenc Group56.01%DBVTDBV Technologies71.74%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/ACRLBFCresco LabsN/ACURRCurrenc Group17.80%DBVTDBV Technologies1.44%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/ACRLBFCresco Labs2,900491.02 millionN/ANot OptionableCURRCurrenc Group246.53 million38.25 millionN/ADBVTDBV Technologies8027.39 million27.00 millionOptionableCURR, CRLBF, DBVT, and AARD HeadlinesRecent News About These CompaniesHC Wainwright Predicts Weaker Earnings for DBV Technologies3 hours ago | marketbeat.comWhat is Lifesci Capital's Estimate for DBVT Q3 Earnings?3 hours ago | marketbeat.comDBV Technologies (NASDAQ:DBVT) Posts Earnings Results, Misses Estimates By $1.27 EPSJuly 30 at 7:26 PM | marketbeat.comDBV Technologies S.A.: DBV Technologies Reports Second Quarter and Half-Year 2025 Financial ResultsJuly 30 at 4:52 AM | finanznachrichten.deDBV Technologies Reports Progress in Clinical Trials and FinancingJuly 29, 2025 | tipranks.comDBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the ReportJuly 29, 2025 | globenewswire.comDBV Technologies Reports Second Quarter and Half-Year 2025 Financial ResultsJuly 29, 2025 | globenewswire.comHalf-Year Report on the DBV Technologies Liquidity Contract with ODDO BHFJuly 28, 2025 | globenewswire.comDBV Technologies (DBVT) Projected to Post Quarterly Earnings on TuesdayJuly 27, 2025 | americanbankingnews.comDBV Technologies Announces Appointment of James Briggs as Chief Human Resources OfficerJuly 22, 2025 | globenewswire.comDBV Technologies (DBVT) Projected to Post Earnings on TuesdayJuly 22, 2025 | marketbeat.comDBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of "Moderate Buy" from AnalystsJuly 22, 2025 | marketbeat.comDBV Technologies (NASDAQ:DBVT) Rating Lowered to "Sell" at Wall Street ZenJuly 19, 2025 | marketbeat.comDBV Technologies (NASDAQ:DBVT) Stock Crosses Above 50-Day Moving Average - Here's What HappenedJuly 15, 2025 | marketbeat.comDBV Technologies Begins Pivotal Peanut Allergy Study, Aims for 2026 FDA Submission.July 9, 2025 | msn.com12 Best Performing NASDAQ Stocks According to AnalystsJuly 8, 2025 | insidermonkey.comDBV Technologies (NASDAQ:DBVT) Upgraded to Hold at Wall Street ZenJuly 5, 2025 | marketbeat.comDBV Technologies S.A. (DBVT) - Yahoo FinanceJuly 4, 2025 | finance.yahoo.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old - MorningstarJune 26, 2025 | morningstar.comMDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 26, 2025 | uk.finance.yahoo.comDBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years OldJune 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm: Undervalued Chip Stock in Breakout UptrendBy Sam Quirke | July 17, 2025View Qualcomm: Undervalued Chip Stock in Breakout UptrendCameco's 80% 3-Month Gain May Be Just the StartBy Jeffrey Neal Johnson | July 17, 2025View Cameco's 80% 3-Month Gain May Be Just the StartWhy Now Could Be the Smartest Time to Buy Crypto StocksBy Nathan Reiff | July 10, 2025View Why Now Could Be the Smartest Time to Buy Crypto StocksQualcomm’s Hold Rating Misses Strong Growth StoryBy Jeffrey Neal Johnson | July 4, 2025View Qualcomm’s Hold Rating Misses Strong Growth StoryHomebuilding Headwinds Putting These 3 Stocks Under PressureBy Dan Schmidt | July 27, 2025View Homebuilding Headwinds Putting These 3 Stocks Under PressureCURR, CRLBF, DBVT, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$12.13 +0.12 (+1.00%) As of 08/1/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Cresco Labs OTCMKTS:CRLBF$0.62 +0.03 (+4.48%) As of 08/1/2025 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Currenc Group NASDAQ:CURR$1.99 +0.19 (+10.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.94 -0.05 (-2.51%) As of 08/1/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Currenc Group, Inc. engages in operating a fintech banking platform. It operates through the following segments: Remittance Services, Sales of Airtime, and Other Services. The company is headquartered in Singapore.DBV Technologies NASDAQ:DBVT$9.00 +0.49 (+5.76%) Closing price 08/1/2025 03:58 PM EasternExtended Trading$9.03 +0.03 (+0.33%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
